Is HRMY a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Harmony Biosciences Holdings, Inc. (HRMY) rests on WAKIX is still accelerating in year seven: Second-quarter net product revenue of ~$261.3M grew 30% year over year, and average patients rose by ~450 in the quarter, the second-largest quarterly patient gain the company has reported. The bear case rests on one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. Analysts covering it publish targets from $32.00 to $70.00 against a $32.96 share price on November 16, 2026, so even the professionals disagree by 79% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

HRMY key stats

At $32.96 on November 16, 2026, Harmony Biosciences Holdings, Inc. (HRMY) has a market cap of $1.9B and a P/E of 10.9 on trailing earnings (5.4 on forward earnings).

Market cap
$1.9B
P/E (trailing)
10.9
P/E (forward)
5.4
EPS (trailing 12 months)
$3.02
Price to book
1.8
Beta
0.98

Market cap, P/E and yield are measured at the $32.96 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Harmony Biosciences Holdings, Inc. (HRMY)?

The last two weeks for Harmony Biosciences Holdings, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • HRMY closed at $32.96 on November 16, 2026, down 2.4% over the past five trading days (from $33.78).
  • On November 4, 2026, Harmony Biosciences Holdings, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 4, 2026, Harmony Biosciences Holdings, Inc. filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Harmony Biosciences Holdings is a commercial-stage neuroscience company based in Plymouth Meeting, Pennsylvania, that licensed pitolisant from the French firm Bioprojet in 2017 and brought it to the U.S. market as WAKIX in 2019. WAKIX is a histamine H3 receptor antagonist and inverse agonist, and it is the only FDA-approved narcolepsy treatment that is not a scheduled controlled substance, which matters commercially because prescribers and patients avoid the paperwork and stigma attached to oxybate and stimulant options. Approvals have widened over time: excessive daytime sleepiness in adults in 2019, cataplexy in adults in 2020, and pediatric patients aged six and up in 2024 and 2026. The company reports a single segment, sells only in the United States, and had roughly 8,950 average patients on therapy in the second quarter of 2026 against a U.S. diagnosed narcolepsy population it estimates at about 80,000. The investment picture turns on a countdown. WAKIX generated ~$261.3M in Q2 2026, up 30% year over year in its seventh year on the market, and the company reiterated full-year guidance of ~$1.0B to ~$1.04B. Trailing twelve-month revenue is ~$959.9M with ~$181.3M of net income and ~$3.09 in diluted EPS, so at ~$38.42 on October 16, 2026 the shares change hands near 12 times trailing earnings, which is closer to how the market prices a specialty pharma in run-off than a company growing 30%. Harmony's own IP disclosure supports WAKIX exclusivity to March 2030 including a six-month pediatric extension, and six of the seven generic filers have settled to license dates in 2030. Against that, the company is spending its cash flow on a pitolisant franchise extension (a gastro-resistant formulation with an April 2027 PDUFA date, a high-dose version in Phase 3, and a Phase 3 trial in Prader-Willi syndrome), on the orexin-2 receptor agonist BP-205, and on clemizole in rare epilepsies. Whether any of that replaces WAKIX revenue is the whole question, and none of the late-stage readouts land before 2027. The stock has had a mixed 2026. It closed at $38.42 on October 16, up ~2.8% year to date and ~48% over twelve months, but down ~8.6% over the past month after Harmony announced on October 12 that CEO Jeffrey Dayno will retire at the end of 2026, with COO Peter Anastasiou taking over as President and CEO on January 1, 2027. The same release reiterated the ~$1.0B to ~$1.04B WAKIX guide. Third-quarter results are scheduled for November 3, 2026, where consensus looks for ~$274M of revenue and ~$1.47 of EPS.

The bull case: what would have to be true for $70.00

The most optimistic published target on HRMY is $70.00, +112.4% from the $32.96 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. WAKIX is still accelerating in year seven

Second-quarter net product revenue of ~$261.3M grew 30% year over year, and average patients rose by ~450 in the quarter, the second-largest quarterly patient gain the company has reported. Harmony expanded its field sales, remote sales, field reimbursement and patient outreach teams during the quarter and launched an online portal aimed at shortening the time from prescription to first fill. Most branded drugs are decelerating by this point in their life cycle, and the fact that this one is not is what supports the ~$1.0B to ~$1.04B full-year guide. Analysts expect the trend to continue: Q3 2026 consensus sits at ~$274M of revenue, about 36% above the prior-year quarter, with results due November 3.

2. The pitolisant franchise extension is the answer to 2030

Harmony licensed next-generation pitolisant rights from Bioprojet in 2022 and has three shots on goal from the same molecule. Pitolisant GR, an enteric-coated version aimed at the 80% to 90% of narcolepsy patients with GI symptoms, had its NDA accepted in July 2026 with a target PDUFA date of April 1, 2027. Pitolisant HD is in two Phase 3 registrational trials (ONSTRIDE 1 in narcolepsy and ONSTRIDE 2 in idiopathic hypersomnia) with topline data guided to 2027, and the company has filed utility patents it says could extend the franchise into the 2040s. It also paid $17M for an exclusive license to Novitium's amorphous pitolisant patent, which runs to 2042.

3. BP-205 puts Harmony in the orexin race

BP-205 is an orexin-2 receptor agonist sublicensed from Bioprojet and originally discovered at Teijin Pharma, and management describes it as the most potent OX2R agonist currently in clinical development. Phase 1 single-ascending-dose data reported in August 2026 showed a Tmax of 30 to 75 minutes, a mean half-life near 25 hours supporting once-daily dosing, and no serious or severe adverse events, with headache the most common at roughly 10% of participants. Multiple-ascending-dose data are expected in Q4 2026, a Phase 1b in sleep-deprived healthy volunteers reads out in early 2027, and Phase 2 studies across several CNS indications start in mid-2027. That timeline puts Harmony well behind Takeda and Alkermes in the same mechanism.

4. A billion-dollar balance sheet pointed at business development

Cash, cash equivalents and investments stood at ~$962.5M as of June 30, 2026, against ~$160M of debt, and operations generated ~$120.2M of cash in the first half. Management has said it is prioritizing assets that are in Phase 3, in registration, or already on market, with revenue potential in the 2028 to 2032 window, which is precisely the gap a WAKIX cliff would open. A $200M repurchase authorization from October 2023 has ~$150M remaining, though no shares were bought back in the first half of 2026. That business development push will now run under new leadership: Peter Anastasiou, the current COO and a former board member, becomes CEO on January 1, 2027, and outgoing CEO Jeffrey Dayno stays on as a non-executive advisor through 2027.

The bear case: what would have to be true for $32.00

The most pessimistic published target is $32.00, -2.9% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Harmony Biosciences Holdings, Inc. is worth if the risks below bite instead of the drivers above.

One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. The seventh filer, AET Pharma US, is still litigating in the District of Delaware; a bench trial concluded in February 2026, post-trial briefing is complete, and closing arguments are set for October 22, 2026, with an adverse ruling capable of pulling that date forward. Harmony and Novitium filed a separate infringement suit against AET and its marketing partner Sandoz in April 2026 over the amorphous pitolisant patent (case 26-cv-00453-JLH), and the defendants answered in June with antitrust counterclaims, which introduces a liability the company was not previously carrying. Competitively, the oral orexin agonists in late-stage development at Takeda and Alkermes target the underlying deficiency in narcolepsy type 1 rather than the symptom, and if they reach the market with strong efficacy they could compress WAKIX before its patents expire. Two smaller items also matter: gross margin fell from 81.0% to 75.8% year over year on new Novitium royalties, and leadership is in flux, with the CFO having departed in July 2026 (an interim officer is in place) and the CEO set to hand over on January 1, 2027. The CEO announcement on October 12 sent the shares sharply lower that day, and the stock is down ~8.6% over the past month.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HRMY already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on HRMY

12 analysts cover HRMY, with an average target of $48.08 (+45.9% against $32.96) and a split of 8 buy, 3 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HRMY forecast and price target page.

How is HRMY valued?

Market cap, P/E and dividend yield at today's price are in the HRMY key stats above. The business figures below come from Harmony Biosciences Holdings, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$960M, all from WAKIX, up ~30% year over year in Q2
  • Net income (TTM): ~$181M (profit margin ~19%)
  • Cash and investments: ~$962.5M vs ~$160M debt (June 30, 2026)
  • 2026 revenue guidance: ~$1.00B to ~$1.04B, reiterated October 2026
  • Next earnings: Nov 3, 2026; consensus EPS ~$1.47 on ~$274M revenue

As of October 2026: Netting out the balance sheet leaves an enterprise value near $1.4B against ~$960M of trailing revenue and ~$181M of net income, roughly 1.5 times sales for a business growing 30%, and the forward multiple of about 5.5 times 2027 estimates is lower still. The discount is the price of one product with a 2030 expiry date, a live patent case and a CEO change. The first late-stage pipeline readouts do not arrive until 2027, so near-term moves are more likely to come from WAKIX quarters and the AET ruling.

How do you decide if HRMY is a buy?

Whether HRMY is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold HRMY indirectly through an index or sector ETF before adding more.

What would change your mind on HRMY

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: WAKIX is still accelerating in year seven stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the HRMY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HRMY against your real portfolio and see your actual exposure before deciding.

Your questions about Harmony Biosciences Holdings, Inc.

Ask Walnut's AI anything about HRMY and see how it fits what you own.

FAQ

Is HRMY a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on WAKIX is still accelerating in year seven, with revenue (ttm) at ~$960M, all from WAKIX, up ~30% year over year in Q2. The bear case rests on one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. Analysts covering it are spread from $32.00 to $70.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell HRMY?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $32.00, -2.9% from the $32.96 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for HRMY?

+

WAKIX is still accelerating in year seven. Second-quarter net product revenue of ~$261.3M grew 30% year over year, and average patients rose by ~450 in the quarter, the second-largest quarterly patient gain the company has reported. The most optimistic analyst target on HRMY is $70.00, +112.4% from the $32.96 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for HRMY?

+

One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. The seventh filer, AET Pharma US, is still litigating in the District of Delaware; a bench trial concluded in February 2026, post-trial briefing is complete, and closing arguments are set for October 22, 2026, with an adverse ruling capable of pulling that date forward. Harmony and Novitium filed a separate infringement suit against AET and its marketing partner Sandoz in April 2026 over the amorphous pitolisant patent (case 26-cv-00453-JLH), and the defendants answered in June with antitrust counterclaims, which introduces a liability the company was not previously carrying. Competitively, the oral orexin agonists in late-stage development at Takeda and Alkermes target the underlying deficiency in narcolepsy type 1 rather than the symptom, and if they reach the market with strong efficacy they could compress WAKIX before its patents expire. Two smaller items also matter: gross margin fell from 81.0% to 75.8% year over year on new Novitium royalties, and leadership is in flux, with the CFO having departed in July 2026 (an interim officer is in place) and the CEO set to hand over on January 1, 2027. The CEO announcement on October 12 sent the shares sharply lower that day, and the stock is down ~8.6% over the past month. The most pessimistic published target is $32.00, -2.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Harmony Biosciences Holdings, Inc. do?

+

Commercial-stage rare-neurology company whose sole product, WAKIX (pitolisant), treats narcolepsy, backed by a next-generation pitolisant and orexin pipeline.

What would have to change for HRMY to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (WAKIX is still accelerating in year seven) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Harmony Biosciences actually sell?

+

One commercial product: WAKIX (pitolisant), a histamine H3 receptor antagonist and inverse agonist approved for excessive daytime sleepiness and cataplexy in narcolepsy, in adults and in children six and older. It is the only approved narcolepsy therapy that is not a scheduled controlled substance. All of the company's ~$959.9M in trailing revenue comes from it, and all of it is earned in the United States.

Is Harmony Biosciences profitable?

+

Yes, and substantially so. Trailing twelve-month net income is ~$181.3M on ~$959.9M of revenue, and the second quarter of 2026 alone produced ~$75.4M of net income, or ~$1.28 per diluted share, on ~$89.3M of operating income. First-half operating cash flow was ~$120.2M. That separates Harmony from most companies filed under the biotech label, which are cash-burning and pre-revenue.

When does WAKIX lose patent protection?

+

Harmony's disclosed position is that its IP estate supports WAKIX exclusivity to March 2030, inclusive of a six-month pediatric exclusivity extension it expects to earn on completion of the TEMPO study in Prader-Willi syndrome. Six of the seven generic filers have settled to license dates in 2030, mostly July 2030 if pediatric exclusivity is granted, with Hikma licensed from March 2030. The company argues that later-filed formulation patents could protect parts of the franchise into the 2040s, but those apply to next-generation products rather than the tablet selling today.

Walnut is informational, not investment advice, and gives no verdict on HRMY. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks